Potential role of intermittent fasting on decreasing cardiovascular disease in human immunodeficiency virus patients receiving antiretroviral therapy

doi:10.5493/wjem.v11.i5.66

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 5

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6094)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series.

Item

Count

PDF

360

WORD

125

HTML

3112

Figures (1-4)

216

Sum=3813

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

307

Download

798

Sum=1105

Publishing Process of This Article

Item

Count

Browse

484

Download

692

Sum=1176

Nov 20, 2021 (publication date) through Jul 6, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Exp Med. Nov 20, 2021; 11(5): 66-78
Published online Nov 20, 2021. doi: 10.5493/wjem.v11.i5.66

Full Size Figure Download Figure

Figure 1 Summary of the interplay of the human immunodeficiency virus- antiretroviral therapy related contributing factors to cardiovascular disease and intermittent fasting potential benefits among People living with human immunodeficiency virus.

Citation: Gnoni M, Beas R, Raghuram A, Díaz-Pardavé C, Riva-Moscoso A, Príncipe-Meneses FS, Vásquez-Garagatti R. Potential role of intermittent fasting on decreasing cardiovascular disease in human immunodeficiency virus patients receiving antiretroviral therapy. World J Exp Med 2021; 11(5): 66-78
URL: https://www.wjgnet.com/2220-315x/full/v11/i5/66.htm
DOI: https://dx.doi.org/10.5493/wjem.v11.i5.66